Contents

Search

nipocalimab

Indications: - investigational treatment of myasthenia gravis [1] Dosage: - 30 mg/kg loading dose, then 15 mg/kg every 2 weeks Adverse effects: - headache (14.3%) - muscle spasms (12.2%) - COVID-19 (15.3%) - peripheral edema (11.2%) Mechanism of action: - blocks IgG binding site on the neonatal Fc receptor - reduces serum IgG (total), including pathogenic IgG autoantibodies in generalized myasthenia gravis [1]

General

neurologic agent

References

  1. George J Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis. Phase III trial met primary endpoint at 6 months. MedPage Today October 16, 2024 https://www.medpagetoday.com/meetingcoverage/aanem/112433